Matched patients with chronic hepatitis C (CHC) were treated with monotherapy with intron A, or its combination with ribavirin or pegintron combination with ribavirin. The comparison group consisted of patients with a natural CHC course who received no specific antiviral therapy. The highest treatment efficacy was achieved in use of pegintron with ribavirin. However, this combination was associated with more frequent CNS and skin side effects. Side effects in all the above groups regressed completely for 1-3 months after the treatment.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Effectiveness of 8-week Treatment with Glecaprevir/Pibrentasvir in Treatment-naïve or -experienced HCV Patients: Results from an Observational Retrospective Study in Real-life Settings (ODYSSEY).
J Gastrointestin Liver Dis
December 2024
Digestive Diseases and Liver Transplantation Center, Fundeni Clinical Institute, Bucharest, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Background And Aims: Pan-genotypic ribavirin-free oral direct-acting antivirals, including the glecaprevir/pibrentasvir combination, are recommended for the treatment of most patients with chronic hepatitis C virus (HCV) infection. In Romania, the HCV-infected patient population receiving glecaprevir/pibrentasvir is not well characterized and data on treatment effectiveness is lacking. The ODYSSEY study aimed to provide insights into the characteristics and treatment outcomes of HCV-infected Romanian patients receiving 8-week therapy with glecaprevir/pibrentasvir.
View Article and Find Full Text PDFIdentification of oxidative stress-related biomarkers in uterine leiomyoma: a transcriptome-combined Mendelian randomization analysis.
Front Endocrinol (Lausanne)
December 2024
Department of Orthopedics, The Affiliated Taian City Central Hospital of Qingdao University, Tai'an, Shandong, China.
Background: Oxidative stress has been implicated in the pathogenesis of uterine leiomyoma (ULM) with an increasing incidence. This study aimed to identify potential oxidative stress-related biomarkers in ULM using transcriptome data integrated with Mendelian randomization (MR) analysis.
Methods: Data from GSE64763 and GSE31699 in the Gene Expression Omnibus (GEO) were included in the analysis.
Effectiveness and Safety of Direct-Acting Antivirals in the Treatment of Chronic Hepatitis C: A Real-life Study in Northeastern Brazil.
Rev Soc Bras Med Trop
November 2024
Universidade Federal do Ceará, Programa de Pós-Graduação em Saúde Pública, Fortaleza, CE, Brasil.
Article Synopsis
- The study evaluated the effectiveness and safety of direct-acting antivirals (DAAs) for hepatitis C, focusing on sustained virologic response (SVR) and serious adverse events among patients in Ceará, Brazil.
- A total of 1075 patients were analyzed, with a high overall SVR rate of 96.4%; however, those with cirrhosis showed slightly lower SVR rates compared to patients with less severe fibrosis.
- While DAAs were generally safe, a small percentage (3.5%) of patients experienced serious adverse events, and some decompensated cirrhosis patients faced mortality during treatment.
A Pangenotypic Hepatitis E Virus Replication Inhibitor With High Potency in a Rat Infection Model.
Gastroenterology
November 2024
Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Virology, Antiviral Drug & Vaccine Research Group, KU Leuven, Leuven, Belgium. Electronic address:
Background & Aims: Hepatitis E virus (HEV) constitutes a substantial public health burden with ∼20 million human infections annually, including 3.3 million symptomatic cases. Appropriate treatment options for, in particular, immunocompromised patients with HEV infection and pregnant women are lacking, underscoring the urgent need for potent and safe antiviral drugs.
View Article and Find Full Text PDFReal-life data of hepatitis C treatment with direct acting antiviral therapy in persons injecting drugs or on opioid substitution therapy.
Infection
November 2024
Gemeinschaftspraxis Am Kaiserplatz, Bonn, Germany.
Article Synopsis
- HCV treatment has significantly improved with direct-acting antiviral therapy (DAA), allowing for shorter treatment durations and better tolerability in difficult-to-treat populations, such as people who inject drugs (PWID) and those on opioid substitution therapy (OST).
- A retrospective analysis of patients receiving DAA at a clinic in Bonn showed that all patients on glecaprevir/pibrentasvir completed their treatment, while 86% of those on sofosbuvir/velpatasvir did, resulting in a 74% sustained virological response (SVR) overall, despite some patients being lost to follow-up.
- The study highlights high adherence and SVR rates for HCV treatment in PWID, supporting efforts to
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!